Urteste SA Cash Flow Conversion Efficiency
Urteste SA cash flow conversion efficiency. Based on the latest financial reports, Urteste SA (URT) has a cash flow conversion efficiency ratio of -0.185x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.41 Million ≈ $-1.21 Million USD) by net assets (zł23.79 Million ≈ $6.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Urteste SA (2019–2025)
Cash flow conversion efficiency of Urteste SA from 2019 to 2025. This chart illustrates how Urteste SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Urteste SA for real-time trading data and today's change.
Urteste SA Cash Flow Conversion Ratio Explained
Urteste SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Urteste SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Urteste SA ranked by their cash flow conversion efficiency. Also see URT market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rajshree Polypack Limited
NSE:RPPL
|
0.072x |
|
Primega Group Holdings Limited Ordinary Shares
NASDAQ:PGHL
|
N/A |
|
Kota Satu Properti Tbk PT
JK:SATU
|
0.014x |
|
Wicaksana Overseas International
JK:WICO
|
0.087x |
|
Zodiac Energy Limited
NSE:ZODIAC
|
-0.145x |
|
Anoto Group AB
ST:ANOT
|
0.251x |
|
Samyang Holdings Corp
KO:000075
|
0.036x |
|
Superhouse Limited
NSE:SUPERHOUSE
|
0.110x |
Annual Cash Flow Conversion Efficiency for Urteste SA (2019–2025)
The table below shows the annual cash flow conversion efficiency of Urteste SA from 2019 to 2025. Review free cash flow generation of Urteste SA to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł34.58 Million ≈ $9.52 Million |
zł10.64 Million ≈ $2.93 Million |
0.308x | +235.68% |
| 2024-12-31 | zł24.11 Million ≈ $6.64 Million |
zł-5.47 Million ≈ $-1.50 Million |
-0.227x | -18.22% |
| 2023-12-31 | zł27.74 Million ≈ $7.64 Million |
zł-5.32 Million ≈ $-1.46 Million |
-0.192x | +71.57% |
| 2022-12-31 | zł5.62 Million ≈ $1.55 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.675x | -154.05% |
| 2021-12-31 | zł9.69 Million ≈ $2.67 Million |
zł-2.57 Million ≈ $-708.19K |
-0.266x | +73.22% |
| 2020-12-31 | zł1.37 Million ≈ $375.68K |
zł-1.35 Million ≈ $-372.56K |
-0.992x | -197.46% |
| 2019-12-31 | zł1.20 Million ≈ $328.95K |
zł-398.48K ≈ $-109.67K |
-0.333x | -- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.